29 June 2018 in Scientific Reports
Lysyl oxidase (LOX) family genes, particularly lysyl oxidase-like protein 2 (LOXL2), have been implicated in carcinogenesis, metastasis, and the epithelial-to-mesenchymal transition (EMT) in various cancers. This study aimed to explore the clinical implications of LOXL2 expression in pancreatic cancer (PC) in the context of EMT status. LOX family mRNA expression was measured in PC cell lines, and LOXL2 protein levels were examined in surgical specimens resected from 170 patients with PC. Higher LOXL2 expression was observed in cell lines from mesenchymal type PC than in those from epithelial type PC. A significant correlation between LOXL2 expression and the EMT status defined based on the expression of E-cadherin and vimentin was observed in surgical specimens (P < 0.01). The disease-free survival and overall survival rates among patients with low LOXL2 expression were significantly better than those among patients with high LOXL2 expression (P < 0.001). According to the multivariate analysis, high LOXL2 expression (P = 0.03) was a significant independent prognostic factor for patients with PC. Additionally, LOX inhibition significantly decreased PC cell proliferation, migration, and invasion in vitro. In conclusion, LOXL2 expression is potentially associated with PC progression, and LOXL2 expression represents a biomarker for predicting the prognosis of patients with PC who have undergone complete resection.
18 May 2014 in Gastric Cancer
The standard of care for stage II/III gastric cancer in Japan is D2 dissection followed by adjuvant S-1 monotherapy. Outcome of patients with stage III disease remains unsatisfactory, calling for a more intensive adjuvant chemotherapy regimen, for which evidence in advanced/metastatic cancer research suggests S-1/cisplatin (CDDP) as a candidate. Although S-1/CDDP was poorly tolerated postoperatively in the previous trial, compliance was dramatically improved by insertion of one cycle of S-1 monotherapy, which delayed administration of CDDP by 6 weeks. A feasibility study of post-gastrectomy S-1/CDDP was performed. Patients with stage III/IV gastric cancer were eligible. The first cycle of chemotherapy consisted of S-1 monotherapy, and intensive antiemetic drugs were prescribed when patients were administered CDDP. The primary endpoint was the completion rate of four cycles of S-1/CDDP. The secondary endpoints were the relative dose intensity, safety, progression-free survival time and overall survival time. Several criteria to skip, postpone or reduce the dose had been predetermined. Between 2010 and 2011, 33 patients were enrolled. Four patients had stage IIIA disease, 7 patients had stage IIIB disease, 11 patients had stage IIIC disease, and 11 patients had stage IV disease. The completion rate of the protocol treatment was 60.6%. The relative dose intensity of S-1 was 77.3% and that of CDDP was 72.3%. The protocol-specified delay in the administration of CDDP dramatically improved the relative drug intensity in the postoperative adjuvant setting, although the completion rate did not reach the expected level.
20 April 2020 in General Thoracic and Cardiovascular Surgery
1 June 2020 in The Japanese Journal of Gastroenterological Surgery
症例は78歳の男性で,健康診断の腹部超音波検査にて肝右葉に腫瘤を指摘され,当院に紹介となった.腹部ダイナミックCTでは,肝右葉に動脈相で濃染する部分を有し,門脈相で低吸収域を呈する8.5 cm大の腫瘤性病変を認め,肝細胞癌と診断した.門脈右枝に対して経皮経肝門脈塞栓術を行った後に,肝右葉切除術を施行した.術中,標本摘出後に超音波検査を施行したところ,残肝の門脈血流が確認されなかった.続けて確認のため術中門脈造影を施行すると,尾状葉のみが造影され門脈左枝以降の血流を認めなかった.肝左葉が右葉のあったスペースへ傾くことによる門脈左枝の捻転による閉塞と診断し,術中に門脈ステント留置を選択,施行した.ステント留置後は門脈血流の速やかな改善を認めた.術後は抗凝固療法を導入し,第23病日に退院となった.術後13か月経過するが,ステント内血栓は認めず良好な門脈血流を維持している.